Desenvolvida pela Immorta Bio, SenoVax elimina células senescentes, combate tumores e melhora a saúde geral em testes pré-clínicos.

Desenvolvida pela Immorta Bio, SenoVax elimina células senescentes, combate tumores e melhora a saúde geral em testes pré-clínicos.

Immorta Bio and TAM Global have achieved a remarkable breakthrough, enhancing the lifespan of mice by over 70%, integrating senolytic therapy and regenerative medicine in a pioneering study.

Background Current barriers to achieving radical life extension include the inability to use syngeneic, youthful mesenchymal stem cells (MSCs) and the anti-regenerative effects of senescence-associated secretory phenotype (SASP) factors. We aim to overcome this by a combination approach in which senescent cell burden is reduced utilizing SenoVax™ a dendritic cell based senolytic immunotherapy combined with syngeneic pluripotent stem cell derived MSC. Methods We induced hepatic injury and accelerated aging using two established murine models: carbon tetrachloride (CCl₄) mediated liver injury and doxorubicin induced systemic senescence. Animals were treated with control, SenoVax, pMSCs or the combination. Outcomes included biochemical and histologic indices of liver injury, circulating and tissue biomarkers of senescence (IL-11, YKL-40, IL-6, IL-23 R) and regeneration (Klotho, FGF-2, neo-VEGF, GDF-11), Results Both CCl₄ and doxorubicin induced a robust senescent phenotype characterized by increased pro-inflammatory and pro-fibrotic mediators and downregulation of regenerative biomarkers. Combined senolytic and pMSC therapy outperformed mono therapies and produced clear synergistic benefits, including significant biochemical improvement of liver failure parameters, reversal of accelerated aging features, and restoration of regenerative signaling pathways. Senolytic monotherapy yielded partial improvements, while pMSCs alone showed limited activity in the presence of a high senescent-cell burden. Conclusions These findings support a mechanistic model in which senescent cells and SASP factors directly suppress MSC-mediated tissue repair. Targeted senolytic immunotherapy enhances the efficacy of regenerative interventions and represents a promising combinatorial strategy for chronic disease management and potentially for modifying biological aging itself. Clinical trial number Not applicable.

Immorta Bio Announces Publication of International Patent Application for SenoVax™, a First-in-Class Senolytic Immunotherapy  Yahoo! Finance Canada

Immorta Bio Announces Publication of International Patent Application for SenoVax™, a First-in-Class Senolytic Immunotherapy  PR Newswire

Immorta Bio has published a study showing over 70% lifespan extension in aging models with its dual-platform therapy, pioneering new paths in age-related health.

Discover how Immorta Bio has achieved a groundbreaking milestone by doubling the lifespan of mice through a novel combination of therapies in aging research.

Immorta Bio has made significant strides in cancer treatment with SenoVax™, which shows promise in reducing tumors in lung, brain, pancreatic, and breast cancers, marking a potential shift in immunotherapy.

Immorta Bio has unveiled a groundbreaking patent application for SenoVax™, an innovative immunotherapy aimed at combating aging and cancer. This first-of-its-kind approach targets senescent cells.

Immorta Bio has unveiled its StemCellRevivify™ platform aimed at regenerating heart, brain, and liver tissues using youthful mitochondria. This breakthrough could change aging treatments.

Immorta Bio's recent research publication outlines a groundbreaking approach to revive coma patients using senolytic immunotherapy and stem cells, marking a significant advancement in medical science.

Immorta Bio's SenoVax™ demonstrates exciting preclinical results for treating Chronic Traumatic Encephalopathy, bridging cancer therapies and neurology.

Renowned lung cancer expert Dr. Gilberto Lopes has joined Immorta Bio's Strategic Advisory Board to advance longevity therapies and immunoncology.

Immorta Bio Inc will present groundbreaking preclinical data on its SenoVax™ immunotherapy for cancer at the AAI Annual Meeting, advancing longevity science.

Immorta Bio's latest study reveals how removing senescent cells boosts natural killer cells, potentially transforming cancer therapies and immune responses.

Immorta Bio will showcase innovative data on its SenoVax senolytic product aimed at treating various cancers at the upcoming SITC Symposium in San Diego.

Immorta Bio will unveil significant advancements in longevity biotechnologies, including SenoVax™ and StemCell Revivify™, at Biotech Showcase 2025.

Immorta Bio's latest research highlights the potential of the SenoVax™ vaccine in transforming lung cancer treatment, showcasing promising animal study results.

Científicos estadounidenses desarrollan SenoVax, una vacuna que elimina células senescentes, ralentiza el envejecimiento y frena el avance del cáncer. Estudios en animales muestran más del 100 % de au...

Scientific Longevity Company Collaborates with Major Academic Institutions to Remove Tumor Defense Mechanisms and Help Defeat Cancer in a Non-Toxic Manner MIAMI, Dec. 4, 2025 /PRNewswire/ -- Immorta Bio today announced the publication of a landmark preclinical study in the Journal of...

Targeting the Root Causes of Aging Demonstrates Powerful Anti-Cancer Activity Across Multiple Tumor Models MIAMI BEACH, Fla., Nov. 25, 2025 /PRNewswire/ -- Immorta Bio Inc., a scientific longevity company pioneering therapies focusing on Treating Diseases of Aging and Treating Aging as...

Newly filed patent describes an unexpected senescence–CTE link; SenoVax™-induced antibodies showed strongest effects among senolytics tested MIAMI, Sept. 24, 2025 /PRNewswire/ -- Immorta Bio, Inc., a scientific longevity company focused on "Treating Diseases of Aging and Treating Aging as...

Company collaborating with FDA to advance senolytic immunotherapy (SenoVax™) into clinical trials for NSCLC MIAMI, Sept. 17, 2025 /PRNewswire/ -- Immorta Bio Inc., a scientific longevity company dedicated to "Treating Diseases of Aging and Treating Aging as Disease™," today announced the...

Longevity Company to Present alongside Pfizer and University of Pittsburgh at Clinical Immunology Symposium MIAMI, May 5, 2025 /PRNewswire/ -- Immorta Bio Inc, a scientific longevity company dedicated to "Treating Diseases of Aging and Treating Aging as Disease", announced it is...